ClinicalTrials.gg
RecruitingNCT07672938MEDIPHENO-HTUpdated Jun 30, 2026

Effects of Hydroxytyrosol-Rich Olive Polyphenol Dietary Supplement Combined With Mediterranean Diet Adherence on the Cognitive Health of Patients With Mild Cognitive Impairment

An interventional study of Low-Dose Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement and High-Dose Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement in Mild Cognitive Impairment (MCI), sponsored by Panhellenic Federation of Alzheimer's Disease and Related Disorders. Recruiting at 1 site in Greece. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Panhellenic Federation of Alzheimer's Disease and Related Disorders · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Mar 2025, registered Jun 2026).
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Cognitive Dysfunction with a site in Greece — 15 open to participants now, 17 under way, 2 of them phase 3. Cognitive Dysfunction · Greece.

Planned enrollment
13th of 22
141 · median 150
Started
2025
with 11 others
No phase
17 of 29
8 open now
Primary completion
2026-12
later than 5 of 16 live
Registered
28th of 29
by date

Among the 29 studies in Cognitive Dysfunction with a site in Greece, this one is the 13th largest by planned enrollment of the 22 interventional ones that give a count, is one of 12 that started in 2025, is one of 17 with no phase, reaches primary completion later than 5 of the 16 other live ones, and was the 28th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

15 of the 29 studies in Cognitive Dysfunction with a site in Greece are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Cognitive Dysfunction with a site in Greece, or all of them as a file.
02

Study summary

Nutrition is an important modifiable risk factor of human cognitive health. Increasing data suggests that certain nutrients or food ingredients, such as plant polyphenols, have the potential to benefit cognitive abilities even in later life. In terms of polyphenols, Hydroxytyrosol (HT) has gained health benefit claims as a potential preventative antioxidant supplementation of neurodegenerative and amyloid-associated diseases while its pharmacological mechanisms suggest protection against cognitive decline. The primary objective of this study will be to evaluate the effects of HT-rich olive juice polyphenol supplementation alongside MeDi adherence compared with placebo alongside MeDi adherence in the prevention of cognitive decline among patients with Mild Cognitive Impairment associated with AD and non-AD pathology.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)

Keywords

  • Dementia Prevention
  • Phenolic-rich Nutritional Intervention
  • Hydroxytyrosol
  • Mediterranean Diet
  • Neurodegenerative Biomarkers
  • Public Health
  • Clinical Trial
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • GR-based men and women aged 50 - 85
  • Willingness and ability to conform to the full protocol.
  • Ability to accept and sign the consent form.
  • Presence of a diagnostic classification of Mild Cognitive Impairment according to the National Institute on Aging and Alzheimer's Association (NIA-AA) framework MCI, which corresponds to stage 3 on the pre-dementia range.
  • score of ≥18 and ≤ 26. Or
  • MMSE (Mini-Mental State Examination) score of ≥26 and ≤ 28.
  • No active suicide ideation based on the Columbia-Suicide Severity Rating Scale.
  • Absence of severe depressive symptomatology based on the Geriatric Depression Scale-15.
  • Not using any laxative drugs for at least three days prior to the screening visit.
  • Information about APOE status

Exclusion criteria

Exclusion Criteria:

  • Patients with mild, moderate, or severe dementia.
  • Current or recent (within the last 4 weeks) engagement with a strict dietary regime i.e., vegetarian / vegan / ketogenic / paleolithic / high protein / weight loss.
  • Any known issues with blood taking.
  • Any known bleeding disorders.
  • Any known allergy to olives, inability to tolerate gluten or multiple allergies/intolerances that would significantly limit food intake.
  • Average alcohol use of >21 glasses per week for men and >14 glasses per week for women (on average for the last six months).
  • History of psychiatric illness including intellectual disability, schizophrenia, bipolar disorder, severe, active depression and alcoholism.
  • Neurologic conditions such as vascular dementia, movement disorders, history of conditions such as anaemia and cancer in the last five years, renal or liver failure, malignant tumours, or organ transplant.
  • Coffee consumption greater than 5 cups per day.
  • > 35 kg/ m2.
  • Not taking a stable dose of statins for at least 3 months before the recruitment visit. Taking antibiotics in the 1 week preceding the recruitment visit.
  • Pregnancy or lactation.
  • Participation in another clinical trial during the last 30 days prior to the recruitment visit.
  • Subject taking supplements that may affect lipoprotein metabolism, >1 g of fish oil/day, antioxidant supplements, cannabidiol (CBD) oil.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
141 participants (estimated)

Study arms

  • Active comparator
    Active Arm - Low Dose

    Low dose: 8 drops (20mg of polyphenols) + Mediterranean Diet instructions

    Dietary Supplement: Low-Dose Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement

  • Experimental
    Experimental Arm - High Dose

    High dose: 16 drops (40mg of polyphenols) + Mediterranean Diet instructions

    Dietary Supplement: High-Dose Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement

  • Placebo comparator
    Placebo Comparator Arm

    Placebo 8 drops + Mediterranean Diet instructions

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementLow-Dose Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement

    This is a prospective, randomised, double-blind, three-arm, placebo-controlled with 1:1:1 randomisation and 52-week follow-up trial. The MEDIPHENO-HTrial study will enrol patients within the Mild Cognitive Impairment spectrum related to AD and non-AD type pathologies. Participants will be randomised to receive either 8 drops of the active HT-high phenolic supplement, or 16 drops of the active HT-high phenolic supplement or 8 drops of the matching placebo. The Mediterranean diet adherence support will be delivered identically to all groups to reduce dietary confounding.

  • Dietary supplementHigh-Dose Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement

    This is a prospective, randomised, double-blind, three-arm, placebo-controlled with 1:1:1 randomisation and 52-week follow-up trial. The MEDIPHENO-HTrial study will enrol patients within the Mild Cognitive Impairment spectrum related to AD and non-AD type pathologies. Participants will be randomised to receive either 8 drops of the active HT-high phenolic supplement, or 16 drops of the active HT-high phenolic supplement or 8 drops of the matching placebo. The Mediterranean diet adherence support will be delivered identically to all groups to reduce dietary confounding.

  • Dietary supplementPlacebo

    This is a prospective, randomised, double-blind, three-arm, placebo-controlled with 1:1:1 randomisation and 52-week follow-up trial. The MEDIPHENO-HTrial study will enrol patients within the Mild Cognitive Impairment spectrum related to AD and non-AD type pathologies. Participants will be randomised to receive either 8 drops of the active HT-high phenolic supplement, or 16 drops of the active HT-high phenolic supplement or 8 drops of the matching placebo. The Mediterranean diet adherence support will be delivered identically to all groups to reduce dietary confounding.

06

What researchers measure

Primary outcomes

  1. Primary: Mean change on the Alzheimer's Disease (AD) Assessment Scale-Cognitive Subscale (ADAS-Cog) total score from baseline to Week 52 compared with placebo

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the cognitive performance of patients with MCI as measured by ADAS-Cog. ADAS-Cog ranges from 0-85 by summing the number of errors made on each task, so that higher scores indicate worse performance.

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Key secondary: Mean change on the Montreal Cognitive Assessment Test (MoCA) total score from baseline to Week 52 compared with placebo

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the cognitive performance of patients with MCI as measured by MoCA. The total possible score for the test is 30 points by summing the number of correct responses given in each task, so higher scores indicate better performance.

    Time frame: From baseline to Week 52

  2. - Mean change on Clinical Dementia Rating - Sum of boxes (CDR-SB) from baseline to Week 52 compared with placebo

    \- The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the CDR-SB, which ranges from 0 to 18, and is calculated by summing the ratings across each of the six domains (memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care), with higher scores indicating greater impairment.

    Time frame: From baseline to Week 52

  3. Mean change on Mini-Mental State Examination (MMSE) from baseline to Week 52 compared with placebo

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the MMSE, which is a 30-point brief screening measure of cognitive status. Higher scores indicate better performance.

    Time frame: From baseline to Week 52

  4. - Mean change on Geriatric Depression Scale-15 (GDS-15) from baseline to Week 52 compared with placebo.

    \- The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on GDS-15, which consists of 15 items and is used to screen for depression in adults. GDS-15 assess mental health based on feelings over the past week, with higher scores on the measure denoting more severe levels of depressive symptoms.

    Time frame: From baseline to Week 52

  5. - Mean change on Short Anxiety Screening Test (SAST-10) from baseline to Week 52 compared with placebo

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on SAST-10, which is a brief questionnaire designed to assess anxiety. SAST-10 scores range from 10 to 40, with higher scores on the measure denoting more severe levels of anxiety symptoms.

    Time frame: From baseline to Week 52

  6. - Mean change on Functional Rating Scale of Symptoms of Dementia (FRSSD) from baseline to Week 52 compared with placebo.

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on FRSSD. The scale ranges from 0 (fully independent) to 42 (fully dependent), with lower scores indicating better daily functioning.

    Time frame: From baseline to Week 52

  7. - Mean change on Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale for use in Mild Cognitive Impairment (ADCS-MCI-ADL) from baseline to Week 52 compared with placebo.

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on ADCS-MCI-ADL, which is a brief questionnaire designed to capture functional abilities (with recall "In the past 4 weeks"). The 18-item ADCS-ADL-MCI is scored from 0 to 53 based on the subject's degree of independence in performing specific tasks. Lower scores on the measure denote more substantial impairment.

    Time frame: From baseline to Week 52.

  8. - Mean change on Quality of life in Alzheimer's disease (QoL-AD) from baseline to Week 52 compared with placebo.

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on QoL-AD, which is a brief 13-item questionnaire designed to assess quality of life. QoL-AD range from 13 to 52, with higher scores indicating better quality of life.

    Time frame: From baseline to Week 52.

  9. - Mean change on - Pittsburgh Sleep Quality Index (PSQI) from baseline to Week 52 compared with placebo.

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on PSQI, which is a questionnaire designed to assess Sleep quality. PSQI range from 0 to 21, with higher scores indicating poor sleep.

    Time frame: From baseline to Week 52.

  10. - Mean change in LDL-C mg/dL cholesterol from baseline to Week 52 compared with placebo.

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on LDL-C mg/dL cholesterol.

    Time frame: From baseline to Week 52

  11. - Mean change in HDL-C mg/dL cholesterol from baseline to Week 52 compared with placebo.

    The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on HDL-C mg/dL cholesterol.

    Time frame: From baseline to Week 52

Other outcomes

  1. Mean percentage change in plasma phosphorylated tau 217 (p-tau217) pg/mL from baseline to Week 52 compared with placebo.

    Exploratory analyses will include blood biomarkers, p-tau217 pg/mL. Mean percentage change in plasma p-tau217 pg/mL from baseline to Week 52 compared with placebo.

    Time frame: From baseline to Week 52

  2. Mean percentage change in plasma levels of beta-amyloid 1-42 (Aβ 1-42) pg/mL from baseline to Week 52 compared with placebo.

    Exploratory analyses will include blood biomarkers, Aβ 1-42 pg/mL. Mean percentage change in plasma levels of Aβ 1-42 pg/mL from baseline to Week 52 compared with placebo.

    Time frame: From baseline to Week 52

  3. Mean percentage change in plasma Glial Fibrillary Acidic Protein (GFAP) pg/mL concentration from baseline to Week 52 compared with placebo.

    Exploratory analyses will include blood biomarkers, GFAP pg/mL. Mean percentage change in plasma GFAP pg/mL concentration from baseline to Week 52 compared with placebo.

    Time frame: From baseline to Week 52

07

Study locations

1 of 1 sites recruiting
  • Palliative Care Centre "Panagia Glykofilousa", Greek Association of Alzheimer's Disease and Related Disorders, Plastira 65, Thessaloniki 54250, Greece.
    Thessaloniki, Central Macedonia 54250, Greece
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 29, 2026
StartActual
Mar 31, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07672938
Lead sponsor
Panhellenic Federation of Alzheimer's Disease and Related Disorders
Collaborators
Palliative Care Centre "Panagia Glykofilousa", Greek Association of Alzheimer's Disease and Related Disorders, Plastira 65, Thessaloniki 542 50, Greece., Levius Vita Foods srl
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Mar 31, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 30, 2026

Study contacts

Magda Tsolaki, Professor Emeritus, MD, PhD
Contact
tsolakim1@gmail.com
+30 2310316143
Vilma Chalili
principal investigator · School of Medicine, Aristotle University of Thessaloniki
Magda Tsolaki
study chair · First Department of Neurology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion